Status:

COMPLETED

Efferon LPS Hemoperfusion for Treatment of Patients With Septic Shock

Lead Sponsor:

Efferon JSC

Conditions:

Septic Shock

Eligibility:

All Genders

18-80 years

Brief Summary

Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\\o...

Detailed Description

Introduction. Sepsis, according to the latest consensus definition (SEPSIS-3, 2016), is a disease characterized by life-threatening organ failure resulting from a disordered regulation of the body's re...

Eligibility Criteria

Inclusion

  • Gram-negative agents in the blood; or detection of an infection focus suggesting Gram-negative agents; or suspected infection based on patient condition, presence of at least two criteria for a systemic inflammatory response and procalcitonin (PCT) level ≥ 2 ng/ml;
  • severity of organ dysfunction assessed on a Sepsis-related Organ Failure Assessment (SOFA) scale \> 4 points as a result of an evident or suspected infection;
  • need for vasopressor support after administration of fluids to maintain an average blood pressure of at least 65 mmHg. and lactate level in serum \> 2 mmol/l (optional, for diagnosis of septic shock).
  • An additional criterion was the endotoxin activity exceeding 0.6 units according to EAA

Exclusion

  • terminal condition,
  • ongoing internal bleeding or high risk of bleeding,
  • severe heart failure (left ventricular ejection fraction \< 25%),
  • decompensated liver failure,
  • body weight less than 20 kg,
  • age \< 18 or \> 80 years.

Key Trial Info

Start Date :

September 13 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 12 2020

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT04884854

Start Date

September 13 2019

End Date

October 12 2020

Last Update

June 3 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

N.I. Pirogov City Clinical Hospital No. 1

Moscow, Russia, 119049

Efferon LPS Hemoperfusion for Treatment of Patients With Septic Shock | DecenTrialz